Mrinal(Laijawala)DutiaMD

Hematologic Oncology

Assistant Professor, Internal Medicine, UC, Davis School of Medicine

Dr. Dutia is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

University of California Davis HealthFellowship, Hematology and Medical Oncology, 2007 - 2010
Alameda Health System-Highland HospitalResidency, Internal Medicine, 2003 - 2007
Grant Medical CollegeClass of 2001

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

PubMed

57 citations
Phase I trial of arginine deprivation therapy with ADI-PEG 20 plus docetaxel in patients with advanced malignant solid tumors
Benjamin K. Tomlinson, Jim Thomson, John S. Bomalaski, Monica Diaz, Taiwo Akande, Nichole Mahaffey, Tianhong Li, Mrinal Dutia, Karen Kelly, I-Yeh Gong, Thomas J. Semra...> ;Clinical Cancer Research. 2015 Jun 1
63 citations
Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma.
Joseph Tuscano, Mrinal Dutia, Karen Chee, Ann Brunson, Christine Reed-Pease, Mehrdad Abedi, Jeanna L Welborn, Robert T. O'Donnell> ;British Journal of Haematology. 2014 May 1
11 citations
Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors
Thomas J. Semrad, Courtney Eddings, Mrinal Dutia, Scott D Christensen, Primo N. Lara> ;Anti-Cancer Drugs. 2013 Jul 1
31 citations
Risk assessment models for cancer-associated venous thromboembolism
Mrinal Dutia, Richard H. White, Theodore Wun> ;Cancer. 2012 Jul 15
Phase I study of temsirolimus (Tem) and pazopanib (Paz) in solid tumors with emphasis on renal cell carcinoma (RCC).
Semrad TJ, Eddings C, Dutia MP, Christensen S, Lau D, Lara P> ;J. Clin. Oncol.. 2011-05-20
Join now to see all